Germany · Delayed Price · Currency is EUR LANXESS Aktiengesellschaft Earnings Call Transcripts
Fiscal Year 2026
-
Amid a challenging market, sales and EBITDA declined, but debt was halved and liquidity remains strong. Strategic restructuring, cost-saving programs, and sustainability initiatives are underway, with a stable dividend proposed and cautious optimism for future recovery.
-
Q1 2026 saw a slow start but improved momentum in March, with Q2 expected to show strong sequential gains driven by both volume and pricing. Full-year guidance is maintained, supported by cost savings and positive segment trends, though geopolitical risks remain.
-
Q1 2026 saw sales and EBITDA decline sharply year-over-year, but March brought improving demand and volumes. Full-year EBITDA guidance is maintained, with price increases underway and cost discipline in focus amid ongoing geopolitical and supply chain risks.
Fiscal Year 2025
-
Full-year EBITDA met guidance at €510 million, with net debt reduced and strong liquidity maintained. 2026 outlook remains cautious amid geopolitical and market volatility, but cost savings and portfolio focus position the company for recovery if volumes improve.
-
Sales and EBITDA declined sharply year-over-year amid weak demand, high energy costs, and Asian competition. Strategic divestments reduced debt and refocused the portfolio, while a €100 million cost savings program and 550 job cuts were announced. 2026 EBITDA is guided at €450–550 million.
-
EBITDA fell sharply year-over-year due to lower volumes and portfolio changes, with utilization at 67% and ongoing cost-cutting measures. Guidance was lowered to the bottom of the range, and anti-dumping rulings plus market consolidation are expected to support future recovery.
-
A strategic exit process for a polymer JV stake has been initiated, with a fixed value mechanism based on historical EBITDA and a clear timeline for put options in 2026 and 2028. Proceeds will prioritize deleveraging, with potential for share buybacks. Contractual safeguards ensure a structured exit, with further upside possible if performance exceeds benchmarks.
-
Q2 saw continued demand weakness, margin pressure from Chinese imports, and a drop in EBITDA, but strong working capital management led to positive free cash flow and reduced net debt. Guidance for 2025 was lowered, with recovery expected in 2026 as market conditions and government stimulus improve.
-
Despite a challenging macroeconomic and geopolitical environment, earnings and cash flow improved, cost savings exceeded targets, and a stable dividend was proposed. Strategic focus shifted to specialty chemicals, with strong sustainability achievements and ongoing risk management amid global trade tensions.
-
Q1 2025 saw a 32% EBITDA increase year-over-year, driven by segment improvements and normalization in agro, while the early urethane divestiture strengthened the balance sheet. Guidance for 2025 is maintained amid macro uncertainty, with tariff impacts and energy costs closely monitored.
-
Stable sales and a 32% rise in operating income were achieved in Q1 2025, supported by cost savings and portfolio streamlining. EBITDA guidance for the year is confirmed at €600–650 million, with a stronger Q2 expected despite ongoing market uncertainties.
Fiscal Year 2024
-
Profitability improved in 2024 due to cost savings and higher utilization, with EBITDA up 20% year-over-year. The company completed its portfolio shift to specialty chemicals and expects modest demand improvement and further deleveraging in 2025.
-
Q3 2024 saw flat sales but strong volume and EBITDA growth, driven by cost controls and higher utilization. Advanced Intermediates and Additives rebounded, while Consumer Protection lagged due to Saltigo. Full-year EBITDA guidance is maintained despite macro headwinds.
-
Q2 2024 saw a 69% year-over-year EBITDA increase, driven by cost-cutting and improved utilization, though market conditions remain soft. Guidance for 2024 is maintained, with further cash flow and profitability improvements targeted for 2025–2026.